Nov 16, 2017 Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
Sep 18, 2017 Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Sep 11, 2017 Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
Aug 1, 2017 Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
